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ABSTRACT 
 
 
Subcutaneous adipocyte hypertrophy is typically associated with insulin resistance and 
increased risk of type 2 diabetes and predicts its future development independent of obesity. In 
humans, subcutaneous adipose tissue hypertrophy is a consequence of impaired adipocyte 
precursor cell recruitment into the adipogenic pathway rather than lack of precursor cells but 
the molecular events responsible for the restricted adipogenesis remain unclear.  The zinc-
finger transcription factor (Zfp) 423 has been identified as a major determinant of 
preadipocyte commitment and maintained white adipose cell function. Although its levels do 
not change during adipogenesis, ectopic expression of Zfp423 in non-adipogenic cells is 
sufficient to activate peroxisome proliferator-activated receptor gamma (Pparγ) expression 
and to increase the adipogenic potential of these cells.  
In the present work, we have investigated whether Zfp423 is epigenetically regulated and 
whether these events are involved in the restricted adipogenesis in humans with expanded 
subcutaneous adipose tissue. 
We report here that, comparison of uncommitted (NIH-3T3) and committed (3T3-L1)  adipose 
precursor cells revealed that Zfp423 expression increased in parallel with the ability of the 
cells to differentiate into mature adipocytes owing to both decreased promoter DNA 
methylation  and nucleosome occupancy  in the 3T3-L1 compared with NIH-3T3 cells. 
Interestingly, non-adipogenic epigenetic profiles can be reverted in NIH-3T3 cells as 5-
azacytidine treatment increased Zfp423 mRNA levels, reduced DNA methylation at a specific 
CpG site, decreased nucleosome occupancy and induced adipocyte differentiation. These 
epigenetic modifications can also be initiated in response to changes in the pre-adipose cell 
microenvironment, in which bone morphogenetic protein 4 (Bmp4) plays a key role. We 
finally showed that, expression of the ZNF423 human ortholog in adipocyte precursor cells 
from subcutaneous adipose tissue inversely correlated to cell size of the autologous mature 
adipocytes. Promoter methylation at the ZNF423 regulatory region also reflected inappropriate 
subcutaneous adipose cell hypertrophy. As in NIH-3T3 cells, the normal ZNF423 epigenetic 
profile was rescued by 5-azacytidine exposure. 
Thus, our results show that epigenetic events regulate the ability of precursor cells to commit 
and differentiate into mature adipocytes by modulating ZNF423 expression, and indicate that 
dysregulation of these mechanisms accompanies subcutaneous adipose tissue hypertrophy in 
humans. 
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1. INTRODUCTION 
 
 
1.1 Obesity  
 
Obesity is a serious global health challenge, especially in developed and developing 
countries, representing a major health problem that has a priority in public health policies 
(Pardo et al. 2012). The prevalence of obesity has been dramatically rising in the last 30-50 
years (Al-Goblan et al. 2014); indeed, if this trend continue,  an estimated 38% of the world’s 
adult population will be overweight and another 20% will be obese in 2030 (Kelly et al. 2008). 
More than 1 in 3 adults is obese in the United States, Mexico, and New Zealand, and more 
than one in four in Australia, Canada, and Chile. (Fig. 1). 
A positive note is that the overweight rate is almost stabilized in Italy in the past ten years and 
obesity rates are among the lowest in the Organization for Economic Cooperation and 
Development (OECD) countries. Indeed, only 1 in 10 adults is obese in Italy, significantly less 
than the OECD average of 1 in 6 (OECD, update 2014). However, childhood obesity rate is  
notoriously one of the highest (36% for boys and 34% for girls) (OECD, update 2014, Italy). 
 
 
 
7 
 
Figure 1. Prevalence of obesity in adulthood. The maps indicate the adult prevalence of 
obesity respectively in males and females (World Health Organization 2014). 
 
 
Obesity is characterized by an increased body weight due to an altered imbalance between 
energy intake and energy expenditure and is defined as a condition characterized by an excess 
of fat accumulation in adipose tissue, to an extent that impairs both physical and psychosocial 
health (Kopelman 2000).  
In clinical practice, the most simply and widely used method for classifying obesity is the 
body mass index (BMI= body weight in kg/ height in m2), which ranges from underweight 
(<18.5 kg/m2) to severe or morbid obesity (≥40 kg/m2), (Table 1), (World Health Organization 
2014).  
 
 
Table 1. Classification of adult underweight, overweight and obesity according to BMI. 
According to WHO, overweight is defined as a BMI equal to or more than 25 whereas obesity 
as a BMI equal to or more than 30 (World Health Organization 2014). 
 
 
A significant increase in the mortality risk starts as the BMI increases over 25 (Speakman et 
al. 2004). This is because there is a strong correlation between body fat and the incidence of 
several chronic diseases, such as cancer, coronary heart disease and diabetes mellitus. The 
effects of obesity on health outcome appear to be reversible if the person in question loses 
weight; indeed a modest weight loss of 5%-10% of body weight has been shown to 
significantly improve cardiometabolic risk factors (Brown et al. 2015) (Fig. 2). 
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Figure 2. Representation of the most important comorbidities associated with obesity. 
Obesity has a multitude of adverse metabolic health consequences such as diabetes mellitus, 
hypertension, dyslipidemia, and metabolic syndrome (Kopelman 2000). 
 
 
Obesity is a multifactorial disease arising from a complex interaction between genetic, 
developmental, behavioural, and environmental influences (Chung et al. 2008, Speakman et al. 
2004). Evidence for genetic contributions to human obesity is provided by familial clustering 
of increased adiposity, including a three to seven fold increased relative risk among siblings 
(Chung et al. 2008, Allison et al. 1996). Genetic factors are currently estimated to account for 
40–70% of the variance in human adiposity (Chung et al. 2008, Allison et al. 1996). However, 
the dramatic increase in obesity prevalence observed in the last decade seems attributable 
mainly to environmental changes promoting the intake of energy-dense foods and/or reduced 
physical activity (Dalle Grave et al. 2013). To reverse the obesity epidemic, community efforts 
should focus on creating an healthy environment favouring the adoption of healthy behaviours 
through an incisive public health intervention. However, it is doubtful that the obesity-
promoting environment will change in the near future. For this reason, it is essential to 
develop more efficacious strategies to help individuals to adopt a healthy lifestyle in a “toxic” 
environment favouring the development of a positive energy balance (Chung et al. 2008). 
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1.2 Diabetes 
 
Diabetes mellitus is a chronic metabolic syndrome characterized by elevated blood glucose 
levels (hyperglycaemia) caused by defects in insulin secretion, insulin action or both 
(American Diabetes Association 2010). According to the classification recommended by the 
American Diabetes Association, there are three main form of diabetes: type 1 diabetes (T1D), 
type 2 diabetes (T2D), and gestational diabetes mellitus (American Diabetes Association 
2010). 
T1D, once known as insulin-dependent diabetes, is a chronic condition characterized by an 
absolute deficiency of insulin, resulting from an autoimmune mediated destruction of β cells. 
Patients with T1D require a daily injection of insulin for survival. 
T2D is the most common form of diabetes mellitus and is characterized by decreased insulin 
sensitivity, as a result of insulin resistance in peripheral tissue, insulin secretory defect of the 
beta cell and excessive hepatic glucose production (Harrison 2009). The most recent T2D 
treatment guidelines indicate to begin with an individualized approach, consisting initially of 
dietary control and lifestyle modifications, followed by oral hypoglycaemic agents and, if the 
control of glucose homeostasis is not achieved, insulin therapy is required (American Diabetes 
Association 2015). 
The chronic hyperglycaemia associated with diabetes leads to long term macro- and 
microvascular complications. Microvascular complications result from damage to small blood 
vessels and include damage to the nervous system (neuropathy), renal system (nephropathy) 
and eye (retinopathy). The major macrovascular complications include accelerated 
cardiovascular disease resulting in higher risk of coronary artery disease, peripheral arterial 
disease, myocardial infarction, stroke, and limb amputation (World Health Organization 
2010). 
Diabetes may be diagnosed based on either one of the four plasma glucose criteria: 1) fasting 
plasma glucose (FPG) >126 mg/dL, 2) 2 h plasma glucose during a 75-g oral glucose tolerance 
test (OGTT) >200 mg/dL, 3) random plasma glucose >200 mg/dL with classic signs and 
symptoms of hyperglycaemia, or 4) Glycated haemoglobin (HbA1c) level >6.5% (American 
Diabetes Association 2015). T2D mellitus is a common and increasingly prevalent disease, 
representing one of the major and serious public health burden (Tabish 2007). The 
International Diabetes Federation estimates that there are approximately 387 million people in 
the world affected with diabetes and globally, it is expected to afflict around 592 million 
people by 2035 (International Diabetes Federation Atlas 2013) (Fig. 3). The American 
Diabetes Association has released a range of recommendations called Standards of Medical 
Care in Diabetes to improve diabetes outcomes. The recommendations include cost-effective 
screening, diagnostic and therapeutic strategies to prevent, delay, or effectively manage T2D 
and its complications (American Diabetes Association 2014).  
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Figure 3. World Prevalence of diabetes. The International Diabetes Federation Atlas (IDF 
Atlas 2013) figure provides a worrying indication of the future impact of diabetes on the 
global development. 
 
 
1.3 The relationship between obesity and Type 2 diabetes 
 
Obesity and T2D are the major public health problems throughout the world and are 
associated with significant co-morbidities and enormous economic costs. The prevalence of 
overweight and obesity is increasing rapidly worldwide, especially in developing countries.  
There is a strong association between obesity and T2D. Meta-analysis of association studies 
showed a higher relative risk for T2D with BMI above 23 as well as a higher waist 
circumference in both men and women (Fig. 4) (Guh et al. 2009, Yaturu et al. 2011, Ni 
Mhurchu et al. 2006). Particularly, the prevalence of diabetes increase from 2% in individuals 
with a BMI between 25 and 29.9 kg/m2, to 8% in those with a BMI of 30 to 34.9 kg/m2, and 
finally to 13% in those with a BMI greater than 35 kg/m2 (Harris et al. 1998). 
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Figure 4. BMI and type 2 diabetes risk. The relationship between BMI and risk to develop 
type 2 diabetes (Sattar et al. 2014). 
 
 
Prospective studies in overweight non-diabetic adults reveal a 49% increase in the diabetes 
incidence in 10 years for every 1 kg/year increase in body weight and each kg of weight lost 
annually over 10 years was associated with a 33% lower risk of diabetes. Furthermore, studies 
in Pima Indians showed that weight gain was strongly related to diabetes incidence only in 
those who were not initially overweight (Aucott 2008, Resnick et al. 2000). 
Glycaemic control is guaranteed by an accurate balance between insulin secretion by the 
pancreatic β-cells and insulin sensitivity of the peripheral tissues and insulin resistance is a key 
feature of the metabolic syndrome progression to T2D. Decreased insulin sensitivity and 
insufficient insulin production are the two key element in T2D pathogenesis (Yaturu et al. 
2011) and insulin resistance represents the major link between obesity and T2D. In the natural 
history of diabetes, obesity and insulin resistance precede the alterations in glucose 
homeostasis. Insulin resistance in both of these conditions is manifested by decreased insulin-
stimulated glucose transport in adipocytes and skeletal muscle and by impaired suppression of 
hepatic glucose production (Reaven et al. 1995). 
Nevertheless, not all subjects with T2D are obese and many obese individuals do not show 
diabetes or the other metabolic complications typical of obesity (10-30%) (Kloting et al. 
2010). Thus, BMI per se is not a sufficiently sensitive marker of individual risk for obesity-
related metabolic complications. Growing evidence suggest an important role for the regional 
fat distribution in the development of adverse metabolic complications (Karpe et al. 2015; Lee 
et al. 2013). Recently, the subcutaneous adipose tissue is generating increasing interest, 
indeed, its impaired expandability and the consequent inappropriate expansion of adipose cells 
are associated with increased local and systemic inflammation, insulin resistance, and ectopic 
fat accumulation, considered to be the main determinant of the obesity-related metabolic 
complications (Gustafson et al. 2015; Kloting et al. 2014; Sun et al. 2011). 
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1.4 Adipose tissue 
 
Until the late 1940s, adipose tissue was considered an energy storage connective tissue, 
without any implication in the regulation of energy balance (Rosen et al. 2006). 
Over the years, this began to change with the realization that adipose tissue plays a major role 
in nutrient homeostasis, serving as the site for calorie storage, as the source of circulating free 
fatty acids during fasting and as an endocrine organ producing adipose-derived serum factors 
(Rosen et al. 2014). Moreover, the growing incidence of obesity and associated metabolic 
comorbidities has raised the urgency in understanding all aspects of adipose tissue biology.  
Depending on the nature of the adipocytes, the mammalian adipose tissue is divided into two 
functionally distinct forms of fat: white and brown (Fig. 5), (Ronti et al. 2006; Rosen et al. 
2006).  
The white adipocyte is the primary site of energy storage and is characterized by the presence 
of a large unilocular lipid droplet acting as a safe storage compartment for triglycerides 
(Hepler et al. 2017).  
Furthermore, white adipose tissue (WAT) also has mechanical properties, serving to protect 
organs from mechanical damage and secretes hormones and cytokines, termed “adipokines,” 
that regulate glucose homeostasis, lipid metabolism and inflammation (Deng et al. 2010). 
Mammals also contain “brown” adipocytes and theirs main function is to convert chemical 
energy into heat. Brown adipocytes are characterized by their multilocular lipid droplet 
appearance and high mitochondrial content (Hepler et al. 2017, Cannon et al 2004). The 
thermogenic program of brown adipocytes is mediated by the expression of uncoupling 
protein 1 (UCP1) a brown adipose tissue-specific protein located within the mitochondria 
(Klingenberg et al. 1999). 
In addition to brown and white fat depots, prolonged cold exposure or adrenergic signaling 
can induce the formation of subsets of UCP-1 positive cells with a brown-like morphology 
within white fat depots. These inducible cells called ‘‘beige’’ or ‘‘brite’’ adipocytes have an 
overlapping but distinct gene expression pattern compared to classic brown adipocytes (Wu et 
al. 2012). The ability to induce “browning” of WAT in rodents is protective against obesity 
and can reverse insulin resistance in metabolic syndrome (Hepler et al. 2017, Rajakumari et al. 
2013). Some of these effects may be mediated by the thermogenic capacity of these cells; 
others may be mediated by an endocrine function. 
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Figure 5. Distribution of White and Brown/Beige Adipose Tissue in Adults. WAT is organized 
into distinct depots, classified by location as subcutaneous or intra-abdominal. 
The major subcutaneous WAT includes the abdominal, gluteal, and femoral depots. Brown 
adipose tissue depots are located in the cervical, supraclavicular, and paravertebral regions 
in adults (Hepler et al. 2017). 
 
 
1.4.1 Adipose tissue expansion: Subcutaneous vs. Visceral  
 
WAT has an incredible ability to expand its dimension as the request for energy storage 
increases. Expansion of WAT is a physiologically response to caloric excess; however, obesity 
is associated with increased risk for diabetes and insulin resistance. Although weight excess is 
the primary risk factor for T2D obesity is not a homogeneous condition. Indeed, 
approximately 10-30% of obese individuals do not show the associated metabolic 
complications (Appleton et al. 2013; Denis et al. 2013). There is growing interest in better 
identifying clinical parameters correlating with obesity and its associated diseases. Notably 
body fat distribution is one of best predictors of metabolic health in obesity (Karpe et al. 2015; 
Lee et al. 2013). Subcutaneous adipose tissue (SAT) stores more than 80% of total body fat 
and is located beneath the skin; while visceral fat surrounds internal organs, and comprises 
less than 10% of the total fat mass (Hepler et al. 2017). 
WAT is now considered as the center of the disorder and its associated comorbidities 
(Greenberg et al. 2006). Obese people, who preferentially accumulate excess adiposity in the 
visceral region, are at higher risk than those who accumulate adipose tissue in the 
subcutaneous compartment.  
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There is also a dimorphism in the anatomical distribution of fat tissue (Karastergiou et al. 
2012; Hepler et al. 2017). In women, adipose accumulation occurs preferentially in the 
subcutaneous regions; while in men, visceral WAT expansion is more evident and role of sex 
hormones is now well recognized (Davis et al. 2013; Palmer et al. 2015). One possible reason 
for the detrimental effects of visceral adipose accumulation is the location of the depot itself. 
Lipids and metabolites can be released into the portal circulation and affect liver function 
(Rytka et al. 2011). However, the observation that anatomically distinct adipocytes follow two 
different development processes, raises the possibility that they are also functionally (and 
intrinsically) distinct. Adipose depot transplantation experiments in mice indicate that factors 
intrinsic to these depots determine their effect on glucose homeostasis (Tran et al., 2008). 
Indeed, several studies demonstrate that adipocytes, from different fat depots, are functionally 
unique, differing in their ability to undergo lipolysis, lipogenesis, and activate thermogenic 
programs (Lee et al. 2013; Macotela et al. 2012; Wu et al. 2012). Thus, an emerging 
hypothesis is that anatomically distinct WAT depots likely represent distinct “mini-organs.” A 
better understanding of how these distinct depots arise and expand during development may 
lead to therapeutic strategies to alter body fat distribution. 
 
 
1.4.2 White adipose tissue remodeling in obesity: Hypertrophy vs. 
Hyperplasia 
 
In response to nutrient excess WAT expands through the enlargement of existing 
adipocytes (adipocyte hypertrophy) or through the formation of new adipocytes (adipocyte 
hyperplasia) (Hirsch et al. 1969). As shown by several studies, the balance between these two 
mechanisms depends on the location of the fat pad. However, in humans, the mechanisms of 
adipose tissue expansion during obesity are not fully delineated. Analysis of adipocyte size 
and number in adults before and after weight gain suggest that females expand lower-body 
subcutaneous depots through adipocyte hyperplasia while males expand these same depots 
through hypertrophy (Tchoukalova et al., 2010). 
Furthermore, it has been reported that new adipocytes are generated constantly to replace lost 
adipocytes (Spalding et al. 2008), and estimated that the adipocyte half-life is in the order of 
8.3 years (Sun et al. 2011). Moreover, evidence suggest that the number of adipocytes is 
already fixed in childhood and a significant weight loss is associated only with reduction of 
adipocyte size and not of their number (Sun et al. 2011; Spalding et al. 2008). 
Nevertheless, the patterns of fat deposition and expansion vary between people and this 
variance determines the differences found in metabolic disease risk seen among individuals 
with a similar BMI. 
Several analyses of WAT from obese individuals reveal that adipocyte size and number 
correlate well with the risk of metabolic syndrome, independent of BMI (Gustafson et al. 
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2015; Hepler et al. 2017; Kloting et al. 2010). WAT from patients with metabolic syndrome is 
characterized by hypertrophic adipocytes, hypoxia, fibrosis, and inflammation (Gustafson et 
al. 2015; Kloting et al. 2014; Sun et al. 2011). The exact sequence of events is still unclear; 
however, (Fig. 6) the inability of SAT to enlarge through hyperplasia leads to burdened and 
hypoxic adipocytes and in this scenario, adipose cell death can occur, leading to the 
recruitment of immune cells and initiation of inflammation. Indeed, the ability of the WAT to 
act as a safe storage depot is impaired, inducing other peripheral tissues to compensate by 
accumulating inappropriately lipids, including the liver and the skeletal muscle, thus triggering 
local and systemic insulin resistance (Chaurasia et al. 2015;  Perry et al. 2014). On the 
contrary, SAT from metabolically healthy individuals is characterized by numerous and 
relatively smaller adipocytes (Corvera et al. 2014; Kloting et al. 2010). 
 
 
Figure 6. White Adipose Tissue Expansion in Obesity. Expansion of white adipose tissue in 
response to caloric excess occurs through the enlargement of existing adipocytes 
(hypertrophy) and/or through an increase in adipocyte number (hyperplasia). Pathologic 
expansion through hypertrophy of adipocytes is associated with inflammation, hypoxia, and 
fibrosis, with early onset of insulin resistance. Adipocyte dysfunction leads to the deleterious 
spillover of lipids into non-adipose organs, termed lipotoxicity. Healthy expansion 
through hyperplasia of adipose tissue occurs through the recruitment of preadipocytes and de 
novo adipocyte differentiation. This occurs alongside with angiogenesis and prevents 
or delays the onset of both insulin resistance and ectopic lipid accumulation (Hepler et al. 
2017). 
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1.4.3 Hypertrophic obesity is associated with restricted adipogenesis in SAT 
 
The limited expandability of the subcutaneous adipose tissue leads to an inappropriate 
adipose cell expansion (hypertrophic obesity) with local inflammation and insulin-resistant 
phenotype (Neeland et al. 2012, Weisberg et al. 2003). 
Promoting adipose cell recruitment in the subcutaneous adipose tissue rather than merely 
inflating the cells, would be protective from the obesity-associated metabolic complications. 
Previous studies have shown that increased subcutaneous fat cell size in humans negatively 
correlates with insulin sensitivity independent from obesity (Smith et al. 2010), moreover it 
has been shown to be an independent risk factor of T2D in prospective studies (Lönn et al. 
2010). 
In a large study, Smith and colleagues analyzed adipogenic potential of preadipocytes isolated 
from the stromal-vascular fraction (SVF) cells from SAT (Gustafson et al. 2012) finding 
significant differences between donors in the number of cells that underwent adipogenesis 
under identical conditions. In fact, some individuals exhibit only 5–10% of cells undergoing 
differentiation while, in others, 80% of the cells became adipocytes (Gustafson et al. 2012). 
Interestingly, reduced differentiation was seen in individuals characterized by increased 
adipose cell size (hypertrophic SAT), whereas small adipocytes were associated with good 
adipogenesis (Fig. 7) suggesting a causal relationship. It is important to note that poor  
adipogenesis is not due to lack of precursor cells but rather to the inappropriate signaling of 
pathways promoting precursor cell commitment and differentiation (Talchai et al. 2012). 
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Figure 7. Adipogenic potential of human preadipocytes from the subcutaneous adipose 
tissue is associated to the adipose cell size of the donors. SVF preadipocytes were 
differentiated for 21 days in vitro and then stained with Oil Red O to show the lipid droplets 
(top). The negative correlation between the amount of lipids accumulated during 
differentiation and the adipose cell size of the donors is shown (bottom) (Gustafson et al. 
2012). 
 
 
Furthermore, Smith and colleagues (Hammarstedt et al. 2013; Gustafson et al. 2013) have also 
identified the WNT-inducible secreted protein 2 (WISP2) that is highly expressed in early 
adipogenic precursor cells. This protein inhibits adipogenesis by dual mechanisms. In the first, 
cytosolic WISP2 forms a complex with the zinc finger protein 423 (Zfp423) that is a 
transcriptional activator of PPARγ. This complex is dissociated by bone morphogenetic 
protein 4 (BMP4), allowing Zfp423 to enter into the nucleus and initiate Pparγ activation. 
However, WISP2 is also a secreted protein that directly can inhibit Pparγ activation although 
the mechanism is still unclear (Fig. 8), (Hammarstedt et al. 2013; Gustafson et al. 2013). 
Interestingly, they also found WISP2 expression increased in the SAT compared to VAT, 
moreover, WISP2 SAT expression is higher in individuals with hypertrophic adipose tissue 
and correlates  with the ectopic fat accumulation (Gustafson et al. 2013). 
Thus, restricted adipogenesis in SAT is currently considered a novel susceptibility factor for 
T2D and this is also evident in non-obese individuals (Arner et al. 2011).  
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Figure 8. Preadipocyte commitment. Precursor cells are kept undifferentiated by WNT 
activation and WISP2. WISP2 prevents PPARγ activation by binding Zfp423 in the cytosol. 
BMP4 dissociates the complex, allowing Zfp423 to enter in the nucleus and initiate PPARγ 
activation (Hammarsted et al. 2013). 
 
 
1.4.4 Hypertrophic obesity: inflammatory response and ectopic fat 
accumulation 
 
Adipocyte volume is also associated with increased inflammatory circulating factors, 
oxidative stress and an increased infiltration of macrophages within adipose tissue. In SAT, 
these alterations cause the shifting toward proinflammatory adipokines secretion pattern 
(Klöting et al. 2014; Blüher et al. 2013) and the onset of the chronic low-grade inflammation 
(Sell et al. 2012).  
Adipocytes and macrophages can react to these stress stimuli by the activation of stress-
sensing pathways, which may contribute to the deterioration of cellular functions and 
contribute to the metabolic comorbidities associated with obesity (Rudich et al. 2007; Bashan 
et al. 2007). In addition, macrophages may report to other organs the stress and inflammatory 
status of the adipose tissue, leading to secondary organ failure. In conclusion, hypertrophic 
obesity may start a sequence of pathogenic event that contributes to adipose tissue dysfunction 
and subsequent effects on other tissues (Blüher et al. 2013).  
Many evidence suggest that both restricted adipogenesis and the impaired tissue 
vascularization capacity are responsible for the onset of metabolic diseases (Gealekman et al. 
2011; Van Harmelen et al. 2004). The inability of SAT to expand proportionally to caloric 
excess represents an important link in the development of adipose tissue dysfunction and 
ectopic fat accumulation (Blüher et al. 2013; Van Harmelen et al. 2004; Bouloumie et al. 
2002),  which is defined as the accumulation of excess energy as fat in locations not 
classically associated with adipose tissue storage (Britton et al. 2011; Gustafson et al. 2007). 
Ectopic fat depots can induce both systemic (as visceral adipose tissue and intrahepatic fat) 
and local effects (as pericardial, myocardial and perivascular fat) (Fig. 9).  
 
 
 
19 
 
 
Figure 9. Ectopic fat classification. Ectopic fat depots in non-adipose tissues, promotes 
systemic and local effects, including dysfunction, insulin resistance and inflammation in the 
liver, muscular tissue, pancreas and visceral fat (Britton et al. 2011). 
 
 
Lipids can accumulate abnormally in hepatocytes, leading to an abnormal fat accumulation in 
the liver that is well known as a non-alcoholic fatty liver disease (NAFLD). NAFLD is 
characterized by various hepatic abnormalities that ranging from hepatic steatosis to 
nonalcoholic steatohepatitis. This condition is extremely prevalent in obesity and is also 
associated with visceral adiposity (Gustafson et al. 2007). The “portal hypothesis” (Rytka et 
al. 2011) suggests that hepatocytes are more exposed to high levels of FFAs and inflammatory 
adipokines increasingly released from the visceral fat tissue into the portal vein of obese 
subjects. The resulting accumulation of fat in hepatocytes can lead to hepatic insulin 
resistance, impairment in the insulin-mediated suppression of hepatic glucose production and 
hence fasting hyperglycaemia (Lee et al. 2014).  
The epicardial adipose tissue under normal conditions fulfills several physiologic functions, 
including acting as an energy source to the myocardium by releasing fatty acids (Gustafson 
2010; Gustafson et al. 2007; Talman et al. 2014). However, epicardial fat may directly affect 
the coronary arteries and myocardium through paracrine actions of locally secreted adipokines 
and other bioactive molecules (Ricote et al. 1998; Tannock et al. 2004), which promote 
macrophage infiltration into adipose tissue, and locally reduce insulin-induced vasodilatation, 
leading to vasoconstriction (Chen et al. 2001). 
These alterations might have long-term effects on cardiovascular function and morphology 
and might be responsible for cardiovascular disorders (Ricote et al. 1998). 
 
 
 
 
20 
 
1.5 Adipogenesis 
 
Adipocytes derive from pluripotent mesenchymal stem cells (MSCs) having the capacity to 
develop into several cell types, including adipocytes, myocytes, chondrocytes and osteocytes. 
These stem cells are located in the vascular stroma of adipose tissue as well as in the bone 
marrow, and, when appropriately stimulated, undergo a multistep process of commitment in 
which the progenitor cells become restricted to the adipocyte lineage. Recruitment to this 
lineage gives rise to preadipocytes that then differentiate into adipocytes (Fig. 10), (Tang et al. 
2012). 
  
 
Figure 10: Stages of adipocyte differentiation. 
Multipotent stem cell with the capacity to differentiate along mesenchymal lineages of 
myoblast, chondroblast, osteoblast and adipocyte, gives rise to preadipocyte. When exposed to 
appropriate environmental and gene expression conditions, these cells undergo clonal 
expansion and subsequent terminal differentiation; cells enlarge in size while accumulating 
lipid vacuoles that fill the cells. 
(Adapted from Romao et al. 2011, Ricoult et al. 2013). 
 
 
Adipogenesis can be divided into two phases: determination and terminal differentiation. 
Determination results in the conversion of the stem cell into a preadipocyte, which cannot be 
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distinguished morphologically from its precursor cell but has lost the potential to differentiate 
into other cell types. In the second phase, the terminal differentiation, the preadipocyte takes 
on the characteristics of the mature adipocyte that acquires the necessary machinery for lipid 
transport and synthesis, insulin sensitivity and the secretion of adipocytes-specific proteins 
(Rosen et al. 2006). All of these steps are controlled by a network of interacting transcription 
factors operating to coordinate the expression of many hundreds of proteins responsible for 
establishing the mature fat cell phenotype (Louet et al. 2007). 
The molecular regulation of terminal differentiation is more extensively characterized than 
determination because of the use of cell lines that have a restricted potential to differentiate 
into other cell types such as 3T3L1 and 3T3-F442A murine cells. 
Adipogenesis, and in particular terminal differentiation, includes a series of transcriptional 
processes involving the sequential expression of several transcriptional factors, culminating in 
the activation of CCAAT/enhancer-binding protein C/EBPs and PPARγ (Fig. 11). 
 
 
Figure 11: A complex transcriptional cascade regulates adipogenesis. 
The transcriptional control of adipogenesis involves the activation of a variety of transcription 
factors. These proteins are expressed in a cascade in which C/EBPβ and C/EBPδ are among 
the earliest seen. These two proteins induce the expression of PPARγ, which in turn activates 
C/EBPα. C/EBPα feeds back on PPARγ to maintain the differentiated state. ADD-1/SREBP-1 
can activate PPARγ by inducing its expression as well as by promoting the production of an 
endogenous PPARγ ligand. All these factors contribute to the expression of genes that 
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characterize the terminally differentiated phenotype. (Adapted from Louet et al. 2007; 
Ahmadian M et al. 2013). 
 
PPARγ is a member of the nuclear receptor super-family that plays an important role in the 
control of gene expression linked to a variety of physiological processes. Its most notable 
function is to regulate development of adipose tissue, which involves coordinating expression 
of many hundreds of genes responsible for the establishment of the mature adipocyte 
phenotype (Tontonoz et al. 1994; Evans et al. 2004; Farmer 2005). 
In addition to Pparγ, Zfp423 was recently identified as a transcriptional regulator of 
preadipocyte commitment (Gupta et al. 2010). Indeed, it has been reported that the Zfp423 
transcription factor is enriched in adipogenic fibroblast cell lines, relative to non-adipogenic 
cells. Although Zfp423 is not increased during adipogenesis, ectopic expression of Zfp423 in 
non-adipogenic cells is sufficient to activate Pparγ expression and markedly increases the 
adipogenic potential of these cells. Conversely, reduction of Zfp423 expression in 3T3-L1 
preadipocytes or mouse embryonic fibroblasts blunts preadipocyte Pparγ expression and 
diminishes the ability of these cells to differentiate (Gupta et al. 2010). 
Another important signalling pathway involved in the regulation of commitment and 
adipogenesis is the canonical wingless-type mouse mammary tumor virus (MMTV) 
integration site family (WNT) signaling pathway (Isakson et al. 2009; Logan et al. 2004). 
WNT family members (WNTs) are secreted glycoproteins that regulate adult tissue 
homeostasis and remodeling by autocrine and paracrine mechanisms (Logan et al. 2004). 
WNTs exert their effects by signaling through multiple so-called ‘canonical’ and ‘non-
canonical’ pathways to control cell proliferation, survival, fate and behavior. Indeed, various 
reports have implicated WNT signaling in regulating mesenchymal stem cell proliferation, fate 
determination and preadipocyte differentiation (Christodoulides et al. 2009). 
 
 
1.6 Epigenetic and adipogenesis 
 
Obesity results from interactions between environmental and genetic factors. Despite a 
relatively high heritability of obesity (40–70%), the search for genetic variants contributing to 
susceptibility has been a challenging task. Genome wide association (GWA) studies have 
identified more than 40 genetic variants associated with obesity and fat distribution. However, 
since these variants do not completely explain the heritability of obesity, other forms of 
variation, such as epigenetics marks, must be considered (Herrera et al. 2011). 
Epigenetics can be defined as the study of heritable changes which affect gene function 
without modifying the DNA sequence (Choi et al. 2013) and could serve as a plausible link 
between the environment and alterations in gene expression that might lead to disease 
phenotypes (El-Osta et al. 2008). 
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Failures in imprinting are known to cause extreme forms of obesity (e.g. Prader Willi 
syndrome), but have also been convincingly associated with susceptibility to obesity. 
Furthermore, environmental exposures during critical developmental periods can affect 
epigenetic profile and result in obesity (Herrera et al. 2011). 
Increases in adipose tissue mass and obesity are closely associated with recruitment of 
adipogenic transcription factors and chromatin remodeling enzyme. For example, a well-
known adipogenic transcription factor, C/EBP promoter, is hypermethylated in differentiated 
3T3-L1 adipocytes (Martínez et al. 2014). 
Several studies have reported that epigenetic regulatory mechanisms are involved in both the 
commitment of pluripotent precursor cells to committed preadipocyte, and in the 
differentiation of preadypocytes to mature adipocytes (Musri et al. 2010). In particular, a 
bioinformatic analysis of the CpG islands in the promoter regions of obesity-related genes  
identified regions with a high density of CpGs in genes implicated in adipogenesis and 
inflammation such as Pparγ, phosphatase and tensin homolog, leptin  and tumor necrosis 
factor α (Martínez et al. 2014). Methylation of these CpG islands influences local chromatin 
structure and function and participates to the regulation of gene expression (Deaton et al. 
2011). The role of epigenetics in adipogenesis can be explained by focusing on PPARγ, the 
master regulator of the adipocyte differentiation. Fujiki and colleagues found that the promoter 
of Pparγ gene was hypermethylated in 3T3-L1 preadipocytes, but methylation decreases 
during differentiation of 3T3-L1 cells and the mRNA expression increases as demethylation 
proceeded (Fujiki et al. 2009). In addition, also late adipogenic genes, such as insulin-
responsive glucose transporter 4 (GLUT4) and leptin (LEP), are demethylated during 
adipogenesis, which corresponds to the expression of these genes in mature adipocytes 
(Pinnick et al. 2011). All together, these studies provided a high-resolution view of chromatin 
remodeling during cell differentiation and allowed the designation of thousands of putative 
preadipocyte- and adipocyte-specific cis-regulatory elements based on dynamic chromatin 
signatures (Martinez et al. 2014). 
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2. AIM OF THE STUDY 
 
Hypertrophic obesity is typically associated with the development of insulin resistance and 
T2D.  In humans, SAT hypertrophy appears to be a consequence of impaired adipocyte 
precursor cell recruitment into the adipogenic pathway rather than lack of precursor cells. 
While the underlying mechanisms have only been partially elucidated, current evidence 
indicates that restricted adipogenesis in SAT predicts future development of T2D independent 
of obesity. However, the present understanding of SAT expansion in human obesity and 
diabetes is limited by incomplete understanding of the molecular basis of preadipocyte 
determination. 
Previous studies demonstrated the importance of the Pparγ transcriptional activator Zfp423 in 
regulating preadipocyte determination and showed that Zfp423 expression identifies 
committed preadipocytes. Thus, Zfp423 is crucial for the initial formation of white adipocytes 
and, importantly, also plays a later role in maintaining the energy-storing phenotype of white 
adipose cells. Furthermore, epigenetic mechanisms have been linked to the transcriptional 
regulation of Zfp423 exerted by Zfp521. These findings support the growing evidence that 
lineage determination of multipotent MSCs to the adipocyte lineage is also epigenetically 
regulated.  
In the present work, we have investigated whether Zfp423 is epigenetically regulated and 
whether these events are involved in the restricted adipogenesis in humans with expanded 
SAT. 
Elucidation of the molecular mechanisms responsible for transcriptional regulation of Zfp423 
may improve the understanding of restricted adipogenesis in hypertrophic obesity and its 
unhealthy metabolic effects. 
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3. MATERIALS AND METHODS 
 
 
3.1 Materials 
 
Media, sera, insulin, TRIzol, and SuperScript-III were from Invitrogen (San Diego, CA, 
USA). Rosiglitazone was from Alexis (Grünberg, Germany). 5-Azacytidine, 3-isobutyl-1-
methylxanthine (IBMX) and dexamethasone (DEX) were from Sigma-Aldrich (St Louis, MO, 
USA). pCpGfree-Lucia was from InvivoGen (St Diego, CA, USA). SYBR-Green was from 
Bio-Rad (Hercules, CA, USA). DNA Methylation Kit was from Zymo Research (Orange, CA, 
USA). Micrococcal Nuclease, Dam-/Dcm- E.coli cells, HpyCH4IV, M.SssI, HhaI and HpaII 
enzymes were from New England Biolabs (Ipswich, WI, USA). DNA Purification Kit and 
pGEM-T-EASY Vector were from Promega (Madison, WI, USA). The PCR Purification kit 
was from QIAGEN (Hilden, Germany). Big Dye Terminator v3.1 Cycle Sequencing Kit was 
from Applied Biosystems (Foster City, CA, USA). 
 
 
3.2 Cell culture and adipocyte differentiation 
 
Mouse embryonic fibroblasts (3T3-L1 and NIH-3T3) used in this study were obtained from 
the American Type Culture Collection (Manassas, Virginia, USA). These mycoplasma-free 
cell lines were grown in DMEM with 10% foetal calf serum (FCS). For adipocyte 
differentiation, cells were grown to confluence in medium containing 10% FCS. Two days 
after reaching confluence, the cells were cultured in DMEM supplemented with a 
differentiation cocktail containing 5µg/ml insulin, 0.5mmol/l IBMX, 1mol/l DEX, 1 µmol/l 
rosiglitazone and 10% fetal bovine serum (FBS) for 2 days. Forty-eight hours after induction, 
cells were maintained in DMEM containing 5μg/ml insulin and 10% FBS until they were 
ready for collection. The NIH-3T3 cells were cultured in the presence or the absence 5-
Azacytidine (5µmol/l) for 6h before the administration of differentiation cocktail. Lipid 
accumulation of mature adipocytes was determined by Oil Red O (ORO) staining as reported 
in [13]. The cells were incubated for 60 min at RT in ORO staining solution. Images were 
taken using an Olympus microscope system (Center Valley, PA, USA). For quantification, 
absorbance was measured at 510 nm using a spectrophotometer (Beckman, CA, USA). 
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3.3 Participants 
 
This study is a secondary analysis on participants from the EUGENE2 consortium (Laakso et 
al. 2008). Adipose tissue derived Stromal Vascular Fraction (SVF) cells were obtained from 
20 healthy non-obese individuals. Recruitment and clinical phenotyping of these individuals 
has been previously described (Laakso et al. 2008). The study was approved by the 
appropriate Institutional Review Boards. All study participants gave informed consent.  
Adipose tissue biopsies were obtained from the abdominal SAT. Following careful dissection, 
the adipose cells were digested with collagenase for 45 minutes at 37°. After the digestion, the 
suspension was centrifuged to obtain two phases: an upper (mature adipocytes) and a lower 
phase (SVF cells). The size of adipocytes was measured according to previously described 
procedures (Isakson et al. 2009, Arner et al. 2011), whereas the SVF cells, in which we 
analysed ZNF423 expression, were cultured in DMEM and Ham's F12 supplemented with 
10% FBS and 0,002 mol/l glutamine as previously reported (Isakson et al. 2009), in order to 
remove the erythrocytes and inflammatory cells.  
 
3.4 RNA isolation and quantitative real-time PCR 
 
RNA was isolated by TRIzol reagent according to the manufacturer’s protocol. The RT-PCR 
of 1µg of RNA was performed using Superscript-III. The cDNA obtained were used as a 
template for qRT-PCR, performed in triplicate by using iQ SYBR Green Supermix on iCycler 
real-time detection system (Bio-Rad). Relative quantification of gene expression is relative to 
the control (equal to 1) and was calculated according to the comparative method of 2-ΔΔCT 
based on the threshold cycle (CT) values of the target and the housekeeping genes.  
The primers used are listed in the table below (Table 2). 
 
Gene Forward/Reverse Primer (5’ to 3’) 
Pparγ2 
mRNA 
Forward 
Reverse 
CAGTGGAGACCGCCCAGGCT  
TGGAGCAGGGGGTGAAGGCT 
Fabp4/Ap2 
mRNA 
Forward 
Reverse 
TCTCACCTGGAAGACAGCTCC 
GCTGATGATCATGTTGGGCTTGG 
Glut4 
mRNA 
Forward 
Reverse 
CAGAAGGTGATTGAACAGAG  
AATGATGCCAATGAGAAA 
AdipoQ 
mRNA 
Forward 
Reverse 
GTGACGACACCAAAAGGGCTC  
TCCAACCTGCACAAGTTCCC 
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Cyclophilin 
mRNA 
Forward 
Reverse 
GCAGACAAAGTTCCAAAGACAG 
CACCCTGGCACATGAATCC 
Zfp423 
mRNA 
Forward 
Reverse 
GGTTTTATTATGTGTTTTTGTAGTGTA 
ATATCCCTCAACTCAACCTACTTAA 
ZNF423 
mRNA 
Forward 
Reverse 
AGGCCTAGAAGGAGAGCCAG  
TCGTCATCACCATCTCCAGG 
Zfp423 NUC 1 
MNase 
Forward 
Reverse 
CCCGCACGGGCCTGTTA  
CTCTGACAGCACTGGGCA 
Zfp423 NUC 2 
MNase 
 
Forward 
Reverse 
TGTGGCCGGACGCCTG  
CCTTCTCCTCCGCCCCTTG 
Zfp423 CTRL R 
MNase 
Forward 
Reverse 
GCCCGAGGGCAGGCA  
GCACGGGCATTGCTCAG 
Zfp423 
Bisulfite 
Forward 
Reverse 
GGTTTTATTATGTGTTTTTGTAGTGTA 
ATATCCCTCAACTCAACCTACTTAA 
ZNF423 
Bisulfite 
Forward 
 
Reverse 
GAGAGGAGGAAGAAATTTAGGGTGGG
GTG 
ACTCAAAACAATCCTCAATACCTAAAA
AAT 
 
Table 2. List of primers used in this study. 
 
3.5 Micrococcal Nuclease (MNase) protection assay 
 
For each experiment, NIH-3T3 and 3T3-L1 cells were fixed for 10 min at 37° in growth 
medium by the addition of 37% (vol./vol.) formaldehyde to a final concentration of 1% 
(vol./vol.). The crosslinking reaction was stopped with glycine (from a 2.5 M stock) to a final 
concentration of 125 mM for 5 minutes at room temperature (quenches reaction). Nuclei were 
isolated from 5×105  cells, suspended in 1 ml of wash buffer (10 mmol/l Tris-HCl (pH 7.4), 15 
mmol/l NaCl, 60 mmol/l KCl and 1mmol/l CaCL2) and digested with 200 U of MNase 
(MNase) for 20 min at 37°. MNase digestion was stopped by adding 100 mmol/l EDTA and 
10 mmol/l EGTA PH 7.5). RNA and proteins were degraded by adding of RNaseA (0,4 
μg/μl), proteinase K (400 μg/ml) and NaCl (300mmol/l). Each sample was adjusted to 0.4% 
SDS and incubated overnight at 65° for deproteinization and crosslink reversal. 
MNase digested DNA were electrophoretically separated on 1.5% agarose gel and 
mononucleosome-size (150 bp) bands were excised from the gel and purified by PCR clean-up 
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and gel extraction (Macherey-Nagel) according to the manufacturer’s instructions. The 
purified DNA was subsequently amplified by quantitative real time RT-PCR using primers 
designed as follows: NUC1, NUC2 and CTRL R primer set for the Zfp423 promoter region. 
 
 
3.6 DNA methylation assessment 
Genomic DNA from cultured cells was extracted by DNA Purification Kit (Promega). 
Bisulfite treatment of extracting genomic DNA was performed by EZ DNA Methylation Kit 
(Zymo Research), following the manufacturer's instructions. The Zfp423 promoter region in 
the bisulfite converted genome was amplified by PCR using Bisulfite-specific primer sets. The 
Bisulfite Primer Seeker software (Zymo Research) was used to design the primers for CG-rich 
sequences. The primers used are listed in the table 2. Converted DNA was amplified under the 
following conditions: 95° for 10 min and 39 cycles of 96° for 1 min, 58° for 1 min, and 72° for 
2 min. For bisulfite sequencing, PCR product was cloned using pGEM T-EASY Vector 
system (Promega). Then, competent E.coli cells were transformed and plated on X-GAL/IPTG 
LB-ampicillin Agar plates, where blue colonies represent an empty vector, and white colonies 
represent vectors inserted with target PCR product. Ten clones from each sample were 
selected and plasmids containing the target DNA are extracted by using the QIAprep Spin 
Miniprep Kit (QIAGEN) and subjected to standard sequencing analysis, using T7 universal 
primer. DNA sequencing was performed on ABI 3500 Automatic Sequencer using Big Dye 
Terminator v3.1 (Applied Biosystems). 
 
 
3.7 In-vitro methylation and luciferase reporter assay 
 
The 5’-flanking region of Zfp423 gene (-1324 to -764) was amplified by PCR and cloned into 
pCpGfree-Lucia (InvivoGen) luciferase reporter vector. Amplification of the reporter 
construct was performed using Dam-/Dcm- E.coli cells (New England Biolabs). The luciferase 
reporter vector was in-vitro methylated by incubation with 1 unit/µg of M.SssI enzyme 
(methylates all CpG) or with 1 unit/ug of HhaI (methylates the cytosines of the sequence 
GCGC) and HpaII enzymes (methylates the cytosines in the sequence CCGG) at 37° for 1h. 
Fully methylated, unmethylated and partially methylated Zfp423 reporter vectors were 
transfected in NIH-3T3. To normalise the luciferase activity, a control plasmid encoding a 
Renilla luciferase gene was cotransfected into the cells. After 48h, Firefly and Renilla 
luciferase activity were assayed using a luciferase reporter assay kit, according to the 
manufacturer’s instructions. 
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3.8 Site-direct mutagenesis and luciferase reporter assay 
 
Zfp423 promoter (-1037/-1002) was amplified by PCR and cloned into the Firefly luciferase 
reporter pCpGfree-promoter-Lucia vector (Invivogen). One-step polymerase chain reaction-
based mutagenesis technique was used to generate site-specific mutation and to produce 
mutated construct (mut). One complementary pair of primers was designed that contained the 
desired mutation, replacing the cytosine at -1016 position with adenine. Both the wt and mut 
constructs were transformed into E.coli GT115 cells (Invivogen). In-vitro methylation was 
performed using the M.SssI methyltransferase following manufacturer’s protocol (New 
England BioLabs). Unmethylated wt and mut constructs were obtained in the absence of 
M.SssI. Methylation was confirmed by resistance to HpyCH4IV digestion (New England 
BioLabs). After 48h, Firefly and Renilla luciferase activity were assayed using a luciferase 
reporter assay kit, according to the manufacturer’s instructions. 
 
 
3.9 Statistical analysis 
 
All experiments were performed three times for each determination and are shown as means ± 
SD. P-values between data sets were determined by two-tailed, unpaired Student’s t-test. 
Significant probability (p)-values are indicated as ***p<0.001, **p<0.01 and *p<0.05. 
Correlation analysis was calculated using Pearson's correlation coefficient. 
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4. RESULTS 
 
 
4.1 Promoter methylation reduces Zfp423 expression in NIH-3T3 cells 
 
Based on the aims above described, the experiments were performed in two cellular models 
with a different adipogenic capability; the 3T3-L1 cells, which are fibroblasts committed to 
adipocyte lineage, widely used to study in vitro adipogenesis; and the NIH-3T3 cells, which 
are fibroblasts with a reduced adipogenic capability and generally used as negative controls 
for in-vitro adipogenesis. 
The mRNA expression of Zfp423 genes was evaluated by quantitative real time RT-PCR 
(qRT-PCR) and found it to be barely detectable in the NIH-3T3 and highly expressed in the 
3T3-L1 cells (p<0.01) (Fig. 1a).  
Importantly, there was no sequence variation of the Zfp423 promoter in NIH-3T3 and 3T3-L1 
cells (data not shown), suggesting that the differential expression observed had not to be 
attributed to the DNA sequences of its promoter, but this remain to be investigated. 
Then, to understand the reasons at the basis of the decreased Zfp423 expression observed in 
NIH-3T3 cells, the contribution of DNA methylation in the transcriptional regulation was 
examined and the specific methylation status of the promoter was determined in-vitro with 
appropriate experimental procedures in both NIH-3T3 and 3T3-L1 cells. We subjected the 
Zfp423 promoter region to bioinformatic analysis. EMBOSS CpGplot revealed a large 560bp 
CpGi upstream Zfp423 transcription start site (TSS), providing a potential basis for 
methylation control of Zfp423 expression. We analysed the methylation status of the Zfp423 
CpGi by bisulfite sequencing in both NIH-3T3 and 3T3-L1 cells and found massive 
demethylation in the latter cell type (15.3% vs. 90.2% in NIH-3T3 cells; p<0.001 Fig. 1b). 
The causal relationship between the methylation status of the Zfp423 promoter and its mRNA 
expression was then evaluated by cloning the Zfp423 promoter region into a luciferase reporter 
(pCpGfree-Lucia) vector, which was completely methylated by M.SssI enzyme, or partially 
methylated by HhaI and HpaII enzymes, or not methylated. Methylation status of these vectors 
was confirmed by digestion with HpyCH4IV, a methylation-sensitive restriction enzyme (data 
not shown). As shown in Fig. 1c, Luciferase activity in the constructs harboring the fully and 
the partially methylated Zfp423 promoters declined, respectively, by 80 and 40% compared to 
the unmethylated promoter (p<0.001). These results demonstrate that methylation regulates 
Zfp423 promoter function in-vitro. 
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Figure 1. Zfp423 mRNA expression and promoter methylation in NIH-3T3 and 3T3-L1 
cells. (a) Total RNA was isolated from the cells and Zfp423 mRNA levels were assessed by 
qRT-PCR. Data normalization was achieved using the housekeeping Cyclophilin gene as 
internal control. Results are the means ± SD from three independent experiments. Statistical 
significance was tested by 2-tail Student’s t-test (**p<0.01). (b) Bisulfite sequencing analysis 
and assessment of Zfp423 promoter methylation of individual methylated CpG sites were 
compared in NIH-3T3 and 3T3-L1 cells [Methylation: 90.2±2.1% NIH-3T3; 15.3±2.7% 3T3-
L1]. Each PCR product was sub-cloned and ten clones were analyzed by bisulfite sequencing. 
Individual CpG sites at the Zfp423 promoter, either methylated (filled circles) or unmethylated 
(open circles), were aligned to their sequence position as indicated on top of the panels. 
Results are the means ± SD from three independent experiments. Statistical significance was 
tested by 2-tail Student’s t-test (p<0.001). (c) Luciferase activity of the in-vitro unmethylated, 
methylated, or partially methylated Zfp423 promoter reporter constructs in NIH-3T3 cells. 
Relative Luciferase activity was normalized against the activity of a cotransfected internal 
vector. Results are the means ± SD of three independent experiments. Statistical significance 
was tested by 2-tail Student’s t-tests (***p<0.001 vs. unmethylated vector, and †p<0.05 vs. 
partially methylated vector). 
  
 
4.2 Nucleosome occupancy of Zfp423 promoter is increased in NIH-3T3 
compared to 3T3-L1 cells 
 
To test whether the differences in Zfp423 gene expression, found in NIH-3T3 and 3T3-L1 
cells, may be linked to different nucleosome occupancy of the gene promoter, the genomic 
sequence was analyzed by the bioinformatic tool NuPoP. Based on bioinformatics analysis, 
Zfp423 promoter exhibits several potential regions where nucleosome positioning featured 
high prediction score (Fig. 2a); suggesting that differential Zfp423 expression in NIH-3T3 and 
3T3-L1 cells is also accompanied by variation in nucleosome occupancy. To validate this 
hypothesis and assess nucleosome occupancy at the best-predicted regions, MNase protection 
assay was performed and nucleosome positioning checked in mono-nucleosomal DNA by 
qRT-PCR (Fig. 2b). Percentage of nucleosome occupancy at two such regions of the Zfp423 
promoter was significantly higher in NIH-3T3 cells (NUC1 % occupancy: 72.2 vs. 51.5 in 
3T3-L1 cells; p<0.01. NUC2 % occupancy: 94.6 vs. 46.4 in 3T3-L1 cells; p<0.001; Fig.2c). 
No significant difference was observed in the CTRL region, where nucleosome positioning 
featured low bioinformatic prediction score. Thus, in these cells, nucleosome occupancy of the 
promoter inversely correlates with Zfp423 expression suggesting that dynamic chromatin 
remodeling may also contribute to transcriptional regulation. 
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Figure 2. Nucleosome occupancy at Zfp423 promoter in 3T3-L1 and NIH-3T3 cells. (a) 
Schematic representation of the regions potentially occupied by nucleosomes at the Zfp423 
promoter in NIH-3T3 and 3T3-L1 cells. Genomic position: NUC1 chr8:87,960,746-
87,960,945; NUC2 chr8:87,959,646-87,959,845; CTRL Reg chr8:87,960,121-87,960,322. (b) 
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Genomic DNA was obtained by lysis of 3T3-L1 and NIH-3T3 cell nuclei and either digested 
with MNase or untreated. (c) The percentage of nucleosome occupancy at two 
bioinformatically-identified regions of the Zfp423 promoter (NUC1 and NUC2) and in 
negative control region (CTRL R) was assessed by qRT-PCR. Nucleosome occupancy across 
the analysed region was quantified by the the 2-ΔCT method using the undigested input as 
normalising control. Dark blue bars represent 3T3-L1 cells; light blue bars represent NIH-
3T3 cells. Results are the means ± SD from three independent experiments. Statistical 
significance was tested by 2-tail Student’s t-tests (**p<0.01, and ***p<0.001 vs. 3T3-L1 cells. 
 
 
4.3 5-Azacytidine enhances Zfp423 expression and allows differentiation 
of non-adipogenic NIH-3T3 cells 
 
To assess whether DNA methylation regulates Zfp423 expression also in intact cells, we 
investigated the ability of the DNA methyltransferase inhibitor 5-Azacytidine (AZA) to 
remove the transcriptional block imposed on Zfp423 in the NIH-3T3 cells. Incubating the cells 
with AZA mainly affected the methylation level at CpG position -1016 (40% methylation in 
exposed vs. 90% in unexposed cells; p<0.01; Fig. 3a) and this was associated with a 6-fold 
increase in Zfp423 mRNA expression (p<0.01; Fig. 3b). However, besides the -1016 CpG, the 
overall methylation profile at Zfp423 promoter does not change in AZA treated cells (data not 
shown), providing a potential explanation for why mRNA expression levels are still lower 
compared to 3T3-L1 cells. Nevertheless, MNase protection studies revealed that AZA 
significantly reduced nucleosome occupancy at the NUC1 and NUC2 regions (p<0.001; Fig. 
3c), further underlining the potential role of chromatin remodelling of the Zfp423 regulatory 
region in transcriptional regulation.  
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Figure 3. Effect of 5-Azacytidine on Zfp423 mRNA expression and nucleosome occupancy 
in NIH-3T3 cells. Cells were cultured in medium supplemented with AZA. (a) Bisulfite 
sequencing analysis of the DNA methylation and percentages of methylated -1016 CpG 
positions in Zfp423 promoter in NIH-3T3 and NIH-3T3+AZA cells [Methylation -1016 CpG: 
90±10% NIH-3T3; 40±10% NIH-3T3+AZA].  Each PCR product was sub-cloned and ten 
clones were analysed by bisulfite sequencing. The methylation profile of each CpG site in the 
Zfp423 promoter, either methylated (filled circles) or unmethylated (open circles), is aligned 
corresponding to its sequence position. Results are the means ± SD from three independent 
experiments. Statistical significance was tested by 2-tail Student’s t-test (p<0.01). (b) 
Expression of Zfp423 mRNA was then measured by qRT-PCR in NIH-3T3 and NIH-3T3+AZA 
cells. Data normalisation has been achieved using the housekeeping Cyclophilin gene as 
internal control. Results are the means ± SD from three independent experiments. Statistical 
significance was analysed by 2-tail Student’s t-test (**p<0.01, and ***p<0.001 vs. NIH-3T3 
cells). (c) The percentage of nucleosome occupancy was analysed by qRT-PCR in the two 
previously identified NUC1 and NUC2 regions of the Zfp423 promoter. The assessment has 
been performed in the absence (dark blue bars) or in the presence (light blue bars) of 5-
Azacytidine. Results are the means ± SD from three independent experiments. Statistical 
significance was tested by 2-tail Student’s t-tests (***p<0.001 vs. NIH-3T3). 
 
In parallel, AZA robustly enhanced expression of Pparγ and the differentiation markers 
Ap2/Fabp4, AdipoQ, and Glut4 after induction of differentiation (Fig. 4a), accompanied by 
>2-fold increased cytoplasmic accumulation of Oil Red O staining (ORO) (Fig. 4b, 4c). Thus, 
in parallel with transcriptional activation, Zfp423 promoter demethylation by AZA also 
promoted differentiation of the non-adipogenic NIH-3T3 cell line.  
a 
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Figure 4. Effect of 5-Azacytidine on NIH-3T3 cell adipogenic differentiation. Cells were 
cultured in the presence (light blue bars) or the absence (dark blue bars) of AZA. Gene 
expression and lipid accumulation were assessed eight days upon the induction of adipocyte 
differentiation. (a) The relative mRNA levels of Pparγ, Ap2/Fabp4, AdipoQ and Glut4 were 
determined by qRT-PCR. Data normalization has been performed using the housekeeping 
Cyclophilin gene as internal control. Results are the means ± SD of three independent 
experiments. Statistical significance was established by 2-tail Student’s t-test (*p<0.05, 
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**p<0.01, and ***p<0.001). (b) At day 8, cells were ﬁxed and stained with ORO. 
Representative microphotographs are shown at two different magnifications (20X, 10X). (c) 
Quantification of ORO staining. Results are the means ± SD of three independent experiments. 
Statistical significance was tested by 2-tail Student’s t-tests (*p<0.05 vs. NIH-3T3). 
 
 
4.4 BMP4 promotes Zfp423 expression by inducing promoter 
demethylation 
 
BMPs are members of the TGF-superfamily that play a key role in inducing adipocyte 
precursor cell commitment towards the adipogenic lineage but the molecular details of their 
action have been only partially elucidated. We found that adding BMP4 to the culture medium 
of NIH-3T3 cells enhanced the expression of Zfp423 by almost 5-fold (p<0.001, Fig. 5a). As 
revealed by bisulfite sequencing, this BMP4-dependent change was accompanied by an almost 
3-fold reduced methylation at position -1016 in the Zfp423 promoter (p<0.01), reminiscent of 
that observed upon 5-Azacytidine treatment (Fig. 5b). 
We, therefore, aimed at establishing the functional significance of the -1016 dinucleotide for 
Zfp423 promoter function by site-directed mutagenesis. After replacement of the cytosine at 
position -1016 with adenine, the 35bp fragment (-1037 to -1002) of the Zfp423 promoter was 
cloned in a Luciferase reporter vector (pCpGfree-promoter-Lucia). Luciferase activity was 
subsequently assayed in NIH-3T3 cells transfected with either the in-vitro methylated or the 
unmethylated promoter. As shown in Fig. 5c, the -1016 mutation did not affect activity of the 
unmethylated Zfp423 promoter. However, the mutation abolished the effect of methylation on 
promoter silencing, indicating that the -1016 dinucleotide modulates Zfp423 transcription in-
vitro. 
a 
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Figure 5. Effect of BMP4 on Zfp423 mRNA expression and promoter methylation in NIH-
3T3 cells. Cells were cultured in medium supplemented with 50ng/ml BMP4. (a) Expression of 
Zfp423 mRNA was measured by qRT-PCR. Results are the means ± SD from three 
independent experiments. Statistical significance was analysed by 2-tail Student’s t-test 
(***p<0.001 vs. NIH-3T3). (c) Bisulfite sequencing analysis of the DNA methylation status 
and percentage of the methylated -1016 CpG position at the Zfp423 promoter in NIH-3T3 
cells upon exposure to BMP4 [Methylation -1016 CpG: 90±10% NIH-3T3; 30±10% NIH-
3T3+BMP4]. Each PCR product was sub-cloned and ten clones were analysed by bisulfite 
sequencing. The methylation profile of each CpG site at the Zfp423 promoter, either 
methylated (filled circles) or unmethylated (open circles), is aligned corresponding to their 
sequence position. Results are the means ± SD from three independent experiments. Statistical 
significance was tested by 2-tail Student’s t-test (p<0.01). (c) Effect of mutagenesis at the -
1016 CpG position on Zfp423 promoter. Disruption of CpG was performed by site-directed 
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mutagenesis as described under Methods. Wild-type and mutated plasmids were treated with 
DNA-methylase M.SssI and transfected into NIH-3T3 cells (light blue bars). Dark blue bars 
represent the untreated plasmids. Luciferase Activity was normalised to Renilla luciferase 
activity. Error bars represent SD from three replicates. Statistical significance was tested by 
2-tail Student’s t-tests (***p<0.001 vs. wild type unmethylated, and †p<0.05 vs. wild type 
methylated). 
 
 
4.5 Preadipocyte ZNF423 expression correlates with mature 
subcutaneous adipose cell size in humans. 
 
To explore the significance of Zfp423 expression in human adipose tissue development and 
function, we first analysed transcription of human ZNF423 (human ortholog of Zfp423) 
(Harder et al. 2013) in preadipocytes from the SVF of 20 healthy non-obese individuals. 
Participants were recruited as described in (Laakso et al. 2008) and their clinical features are 
presented in Table 1.  
 
 Mean ± SD 
N 20 
Age, years 40.8 ± 7.9 
BMI, Kg/m2 25.4 ± 2.6 
Fat percent, % 26.0 ± 6.7 
Free Fat Mass, Kg 57.4 ± 10.4 
Cell size, µm 95.9 ± 9.5 
GIR/bw, mg/min 9.1 ± 3.1 
f-insulin, pmol/l 348 ± 179.4 
fb-glucose, mmol/l 4.6 ± 0.5 
OGTT p-glucose 2h, mmol/l 6.1 ± 1.8 
 
Table 1. Clinical characteristics of the study group. 
 
 
Notably, subcutaneous adipose cell size varies over a broad range even in these non-obese 
individuals which is consistent with different adipogenic potential of the precursor cells. 
ZNF423 mRNA was well detectable in the cells from all and, importantly, expression in the 
preadipocytes exhibited a significant negative correlation with the size of the mature 
subcutaneous adipose cells from these same individuals (Fig.6; r = -0.5258, p<0.05).  This 
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finding shows that low ZNF423 expression in the adipose precursor cells is a marker of 
subcutaneous adipocyte size of the donors and, thus, adipogenesis and the development of 
inappropriate adipose cell hypertrophy and associated insulin-resistant phenotype. 
 
 
 
Figure 6. ZNF423 expression in preadipocytes from non-obese individuals with different 
subcutaneous adipocyte size. ZNF423 mRNA expression was quantitated in preadipocytes 
obtained from the SVF of SAT in n=20 healthy non-obese individuals as described under 
Methods. Correlation was assessed by linear regression analysis (ZNF423: r = -0.525). 
 
 
The central enhancer CpGi at the human ZNF423 locus features >80% homology in mammals 
(Harder et al. 2013) and, based on site-specific mutagenesis studies in leukemia cells, was 
shown to be relevant for the functional regulation of both α and β ZNF423 promoters (Harder 
et al. 2013). In human preadipocytes, we observed that ZNF423α is the predominant isoform 
while ZNF423β is barely detectable (data not shown). 
To further explore the mechanisms determining ZNF423 expression in the SVF preadipocytes, 
we performed bisulfite sequencing of the entire enhancer CpGi in three individuals featuring 
the smallest size in their subcutaneous adipocytes and an equal number of individuals 
exhibiting the largest adipocyte size. All of these individuals were non-obese and had similar 
BMI. This analysis revealed massively increased methylation levels at two sub-regions of the 
CpG enhancer island in these latter individuals (Fig. 7a). Indeed, the R2 sub-region featured 
>90% methylation at CpG dinucleotides 30 and 33 in the participants with subcutaneous 
adipocyte hypertrophy, compared to <20% in those featuring smaller adipocytes, respectively 
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(Fig. 7b). Similarly, the R3 sub-region revealed >90% and <45% methylation at CpG 
nucleotides 54-57, 60, 62 respectively, in the individuals with and without adipose cell 
hypertrophy. In addition, AZA treatment of preadipocytes isolated from individuals with 
adipose cell hypertrophy led to >2-fold increased ZNF423 expression (Fig. 7c). AZA strongly 
decreased the methylation level at CpG positions 54-57, 60, 62 of the R3 sub-region, 
consistent with the important role of these CpG in regulating ZNF423 expression (Fig. 7d). 
Methylation at regions R1 and R2 was not affected by AZA (data not shown).  
Taken together, these data indicate a non-permissive transcriptional state at the ZNF423 locus 
in the SVF precursor cells from individuals who develop inappropriate subcutaneous adipose 
cell hypertrophy, a marker of impaired adipogenesis.  
a 
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d 
 
 
Figure 7. DNA methylation at the ZNF423 promoter in SVF cells from non-obese 
individuals with subcutaneous adipocyte hypertrophy. Genomic DNA from preadipose 
SVF cells was obtained from n=3 of the individuals analysed in Fig. 6 and exhibiting the most 
extreme subcutaneous adipocyte hypertrophy (Hypertrophy) and n=3 individuals featuring the 
lower adipocyte size (CTRL). The individual DNA preparations were exposed to bisulfite as 
described under Methods and individually analysed by PCR amplification of the CpGi at the 
ZNF423 enhancer region (-12.1 Kb; -11.4 Kb). PCR products were then individually 
subcloned and sequenced. (a) Methylation of 65 CpGs at the three ZNF423 promoter regions 
termed R1-R3 is shown for fifteen replica clones. Open and filled circles indicate 
unmethylated and methylated CpGs, respectively. A representative experiment with one 
individual featuring SAT hypertrophy (hypertrophy) and one control individual is shown 
(n=3). (b) Quantification of the methylation levels at eight specific CpGs in individuals 
featuring the smallest size in their subcutaneous adipocytes (dark blue bars) and in individuals 
exhibiting the largest adipocyte size (light blue bars). Error bars represent SD from three 
individuals per group. Statistical significance was tested by 2-tail Student’s t-tests (**p<0.01, 
and ***p<0.001). (c) Expression of ZNF423 mRNA was measured by qRT-PCR. Results are 
the means ± SD from three independent experiments. Statistical significance was analysed by 
2-tail Student’s t-test (**p<0.01 vs. SVF cells). (d) Methylation at the R3 region on ZNF423 
promoter is shown for ten replica clones. Open and filled circles indicate unmethylated and 
methylated CpGs, respectively. A representative experiment of three individual experiments 
with AZA treated/untreated SVF cells from one individual featuring SAT hypertrophy 
(hypertrophy). 
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5. DISCUSSION 
 
 
Previous studies demonstrated the importance of the Pparγ transcriptional activator Zfp423 
in regulating preadipocyte determination (Gupta et al. 2010) and showed that Zfp423 
expression identifies committed preadipocytes (Gupta et al. 2012). Thus, Zfp423 is crucial for 
the initial formation of white adipocytes and, importantly, also plays a later role in maintaining 
the energy-storing phenotype of white adipose cells (Shao et al. 2016). Moreover, epigenetic 
mechanisms have been linked to the transcriptional regulation of Zfp423 exerted by ZFP521. 
ZFP521 binds the promoter and intronic regions of Zfp423 and represses its expression by 
promoting histone modifications. These findings support the growing evidence that lineage 
determination of multipotent MSCs to the adipocyte lineage is also epigenetically regulated 
(Addison et al. 2014). 
Given the central role of Zfp423 in controlling preadipocyte commitment, in this study we 
investigate whether Zfp423 gene is under epigenetic regulation and if this plays a role for the 
early induction of adipogenesis. To this aim, we carried out our study in 3T3-L1 and NIH-3T3 
cells, which are respectively adipocyte lineage committed and non-adipogenic fibroblasts 
(Fujiki et al. 2009).  
In this study, we show that Zfp423 is transcribed in 3T3-L1 preadipose cells but not in NIH-
3T3 non-preadipose fibroblasts. Furthermore, we identified a large CpGi at the Zfp423 
promoter and report, for the first time, that Zfp423 expression in 3T3-L1 cells is accompanied 
by an extensive demethylation of this Zfp423 region, followed by decreased nucleosome 
occupancy. 
This finding implicated a causal relationship between the different epigenetic profile and 
Zfp423 transcription in 3T3-L1 and NIH-3T3 cells. Consistent with this hypothesis, we found 
no DNA sequence variation at the Zfp423 promoter in the two cell types. Luciferase assays 
provided formal proof that methylation directly represses Zfp423 promoter function in-vitro. 
In addition, exposure to the demethylating agent 5-Azacytidine simultaneously caused Zfp423 
promoter demethylation and rescued Zfp423 transcription in intact NIH-3T3 fibroblasts. Thus, 
promoter methylation is an important regulator of the differential transcription of Zfp423 in 
non-preadipose and preadipose fibroblasts. 
DNA methylation inhibits gene expression by at least two mechanisms. Firstly, cytosine 
methylation may directly inhibit the association of DNA binding factors (Fujiki et al. 2009, 
Klose et al. 2006). Secondly, proteins that recognize methylated CpG sites may recruit 
transcriptional corepressor molecules, including histone modification and chromatin 
remodelling enzymes, and cause a transcriptionally repressed chromatin state (Fujiki et al. 
2009, Klose et al. 2006). In our work, MNase digestion assays revealed that, in the preadipose 
 
46 
 
3T3-L1 fibroblasts, the CpG demethylation of the Zfp423 promoter is accompanied by 
nucleosome repositioning in an open chromatin state which may contribute to Zfp423 active 
transcription. The ability of 5-Azacytidine to induce this same nucleosome repositioning 
suggests that, in the NIH-3T3 cells, demethylation of the Zfp423 promoter may trigger 
chromatin remodelling in a transcriptionally active conformation, thereby inducing Zfp423 
expression. Therefore, while direct association of transcriptionally relevant DNA binding 
factors to methylated cytosines was not investigated in this work, CpG methylation-triggered 
chromatin condensation appears to be an important mechanism for maintaining the methylated 
Zfp423 promoter silenced.   
Previous studies demonstrated that Zfp423 transcription is essential for preadipocyte 
commitment, enabling further adipogenic differentiation (Gupta et al. 2010, Gupta et al. 
2012). In line with this, we show that the effect of 5-Azacytidine on Zfp423 promoter 
epigenetics and active gene transcription was followed by rescue of the differentiation 
capacity of the NIH-3T3 fibroblasts as revealed by a robust raise in Pparγ, Ap2/Fabp4, 
AdipoQ and Glut4 levels. ORO accumulation in NIH-3T3 cytoplasm was also increased 
following exposure to 5-Azacytidine. Therefore, in the model we now propose, commitment 
of an adipocyte precursor cell is accompanied by the acquisition of a specific chromatin 
epigenetic signature of the Zfp423 locus (Gupta et al. 2010, Bell et al. 2011). Importantly, as 
shown in this work, these events appeared to be reversible. Indeed, the exposure of the 
uncommitted NIH-3T3 cell to an epigenetic agent, i.e., 5-Azacytidine, reprogrammed in part 
the epigenetic signature at the Zfp423 promoter, favouring commitment and adipogenesis. 
However, 5-Azacytidine does not make the NIH-3T3 cells an in-vitro model of spontaneous 
adipogenesis (data not shown). This is not surprising because Zfp423, identified as a major 
determinant of preadipocyte commitment, is not responsible for the early phase of 
adipogenesis. At this stage, only the ectopic expression of C/EBP-β provides a surrogate for 
the requirement of adipogenic differentiation MIX by NIH-3T3 cells for differentiation (Wu et 
al. 1996). It is possible that further work in this area will generate novel opportunities to 
overcome the restricted subcutaneous adipogenesis which is predictive of type 2 diabetes. 
Studies by Bowers and co-workers (Bowers et al. 2006) have previously demonstrated stem 
cell commitment to the adipocyte lineage by 5-Azacytidine inhibition of DNA methylation. 
These same investigators also provided evidence supporting the role of BMP4 signaling in the 
5-Azacytidine-induced adipocyte lineage determination (Huang et al. 2009). Additional 
studies also revealed that increased expression and secretion of BMP4, a key molecule in the 
adipogenic microenvironment since it is also secreted by mature adipose cells (Gustafson et al. 
2015), correlate with MSCs capacity to undergo adipogenic differentiation (Huang et al. 2009, 
Tang et al. 2004). Importantly, BMP4 was shown to enable nuclear entry of ZFP423 by 
dissociating the cytoplasmic WISP2-ZFP423 protein complex which retains ZFP423 in the 
cytosol (Hammarstedt et al. 2013), thereby activating Pparγ transcription. Silencing Zfp423 
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completely prevents the induction of Pparγ and other adipogenic marker genes in BMP4-
treated cells, showing that ZFP423 is crucial for Pparγ activation as well as for the ability of 
BMP4 to induce Pparγ transcription (Hammarstedt et al. 2013). 
In the present work, we demonstrate, for the first time, that BMP4 also causes demethylation 
of the Zfp423 promoter, which is sufficient to commit otherwise non- adipogenic cells to the 
adipogenic lineage. Thus, convergence of the BMP4 signalling on Zfp423 enables its action on 
preadipocyte determination through multiple mechanisms, including epigenetic modifications 
at key genes and nuclear import of ZFP423.  
Interestingly BMP2, a BMP4 homolog, only slightly reduces Zfp423 expression in NIH-3T3 
cells (data not shown), likely because, as previously reported (Kamiya et al. 2011) the BMP2 
target and Zfp423 inhibitor ZFP521 is expressed in these cells. Addison et al. have indeed 
reported that BMP2-induced commitment of MSC to the adipose lineage is likely suppressed 
by ZFP521 through direct inhibition of Zfp423, providing a potential explanation for why 
BMP2 responses are predominantly osteogenic (Addison et al. 2014). 
Detailed analysis of BMP4 action on Zfp423 transcription revealed that BMP4-induced 
demethylation selectively involved the CpG dinucleotide at position -1016 from the Zfp423 
TSS. Interestingly methylation at this same site was invariably inhibited following 5-
Azacytidine treatment of NIH-3T3 cells. These novel findings suggest a functional relevance 
of the -1016 dinucleotide. In fact, subsequent mutagenesis experiments demonstrated that, 
while not affecting the in-vitro function of the demethylated Zfp423 promoter, the introduction 
of a point mutation at the -1016 CpG position prevented the methylation-dependent silencing 
of Zfp423 transcription. Accordingly, we suggest that the regulatory effect of methylation at 
the Zfp423 promoter is not only dependent upon the quantitative dimension of the methylation 
events but also on the specific promoter region which is affected. 
Restricted adipogenesis in human SAT is determined by impaired adipocyte precursor cell 
commitment and results in hypertrophy of adipocytes in the SAT (Gustafson et al. 2013, 
Isakson et al. 2005, Arner et al. 2010) .  Importantly, our recent studies have shown that 
markers of a restricted subcutaneous adipogenesis with inappropriate adipose cell hypertrophy 
are associated with a family history for type 2 diabetes (Arner et al. 2010, Smith et al. 2016) 
and also present in non-obese individuals with type 2 diabetes (Acosta et al. 2016). The 
relevance of our mechanistic findings in the NIH-3T3/3T3-L1 cell model to human adipose 
tissue dysfunction is underlined by our results in human adipocyte precursors revealing that 
their expression of the Zfp423 human ortholog ZNF423 (Harder et al. 2013) negatively 
correlates with the cell size of mature adipocytes. Hence, in the same individuals, low ZNF423 
expression in SVF preadipocytes is a marker of impaired adipogenesis leading to inappropriate 
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hypertrophy of mature subcutaneous adipocytes and causally contributing to it by interfering 
with precursor cell adipogenic commitment and differentiation.  
Taken together, our present results suggest that the restricted subcutaneous adipogenesis 
associated with insulin resistance and a family history of type 2 diabetes may be due to 
dysfunctional epigenetic regulation rather than conventional DNA risk genes. 
Secretion of BMP4 by mature adipose cells is positively correlated with adipose cells size and 
we have suggested that this is part of a positive feed-back in the tissue to enhance commitment 
and differentiation of new precursor cells to prevent inappropriate hypertrophy (Gustafson et 
al. 2015). We here provide a molecular basis for the effect of BMP4 to enhance adipogenesis 
although secretion of the BMP4 antagonists, in particular Gremlin 1 in man (Gustafson et al. 
2015), is increased in hypertrophic obesity and prevents the expected positive effect of BMP4 
on adipogenesis.  
The overall structure of the regulatory regions of human ZNF423 and mouse Zfp423 is quite 
different (Harder et al. 2013). However, we observed massive hypermethylation at distinct 
CpG dinucleotides in the central island serving as promoter enhancer in human ZNF423. 
Hypermethylation of this same island has been previously shown to silence the gene in human 
leukaemia cells (Harder et al. 2013). The position of the regulatory CpG dinucleotides, which 
are targeted by methylation events in leukaemia and adipocyte precursor cells differ, likely 
reflecting tissue specificity (Ghosh et al. 2010). However, as demonstrated in the leukaemia 
cells, methylation at the preadipocyte ZNF423 central enhancer island may also feature a 
repressive function as its presence closely correlated with the reduced ZNF423 expression in 
the adipocyte precursor cells. We propose, therefore, that changes in the methylation profile at 
the regulatory region account for the reduced ZNF423 expression observed in hypertrophic 
adipose tissue. Indeed, 5-Azacytidine treatment of preadipocytes isolated from individuals 
with adipose cell hypertrophy rescues both the hypomethylated and permissive state at specific 
CpG enhancer region dinucleotides and ZNF423 expression. 
Thus, based on our findings, methylation at the ZNF423 regulatory region and its expression 
can be targeted both pharmacologically (i.e. 5-Azacytidine) and by changes in the 
microenvironment of the adipose tissue (i.e. changes in BMP4 abundance/signaling). 
Expansion of this work may generate attractive and novel opportunities to overcome the 
restricted subcutaneous adipogenesis and prevent inappropriate adipose tissue hypertrophy and 
its negative consequences on metabolism and risk of type 2 diabetes. 
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